Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ COL8A1 Monoclonal Antibody (C3)
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA541571
This item is not returnable.
View return policy
Description
COL8A1 Monoclonal Antibody for Western Blot
The extensive family of COL gene products (collagens) is composed of several chain types, including fibril-forming interstitial collagens (types I, II, III and V) and basement membrane collagens (type IV), each type containing multiple isoforms. Collagens are fibrous, extracellular matrix proteins with high tensile strength and are the major components of connective tissue, such as tendons and cartilage. All collagens contain a triple helix domain and frequently show lateral self-association in order to form complex connective tissues. Several collagens also play a role in cell adhesion, important for maintaining normal tissue architecture and function.
Specifications
COL8A1 | |
Monoclonal | |
1 mg/mL | |
PBS with 50% glycerol and 0.05% ProClin 300 | |
P27658 | |
COL8A1 | |
Recombinant protein Collagen Type VIII Alpha 1. The antigen corresponds to amino acid range 575-743 of the target protein. | |
200 μL | |
Primary | |
Human | |
Antibody | |
IgG2a κ |
Western Blot | |
C3 | |
Unconjugated | |
COL8A1 | |
C3orf7; cell proliferation-inducing protein 41; Col8a1; Col8a-1; Collagen alpha-1(VIII) chain; collagen type VIII alpha 1; collagen VIII, alpha-1 polypeptide; collagen, type VIII, alpha 1; endothelial collagen; procollagen type VIII alpha 1; procollagen, type VIII, alpha 1; smag-64; smooth muscle cell-expressed and macrophage conditioned medium-induced protein smag-64; Vastatin | |
Mouse | |
Protein A/G | |
RUO | |
1295 | |
-20°C | |
Liquid |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction